30 January 2026, LONDON, UK – The END Fund today announced a new initiative backed by GSK, to work together to accelerate progress towards the elimination of neglected tropical diseases (NTDs).
Through this commitment, GSK joins the END Fund’s global community working to deliver the World Health Organization’s 2030 roadmap goals for NTD elimination. The project will be for three years and support country-led efforts.
The majority of funding will focus on eliminating lymphatic filariasis in high-priority countries, while also strengthening data systems and supply chains that underpin reliable access to treatments.
The initiative will support critical advocacy and communications to accelerate more sustainable future drug access models particularly for soil-transmitted helminthiasis.
“The END Fund is deeply proud of its initiative with GSK. For decades, donated medicines have been the lifeblood of the global effort to end NTDs, and a critical motivator for philanthropic investment,” said Dr. Solomon Zewdu, Chief Executive Officer of the END Fund. “With GSK now making a direct financial contribution via the END Fund’s established model for resource mobilization, we are unlocking even greater opportunities to mobilize capital and accelerate the efforts of governments and communities to eliminate NTDs once and for all.”
The move comes at a critical moment for the global fight against NTDs. As health systems face increasing pressure, coordinated initiatives remain essential to achieving the World Health Organization’s 2030 targets and ensuring that hard won gains are sustained.
NTDs threaten approximately 1.5 billion people globally, including nearly 1 billion children. The WHO’s NTD roadmap set the goal of 100 countries eliminating at least one NTD by 2030. As of December 2025, 58 countries have officially eliminated at least one.
The pharmaceutical industry has played a key role in this progress. To date, GSK has supplied over 12 billion treatments globally to combat NTDs.
About the END Fund
The END Fund is a private philanthropic initiative that exists to end the most prevalent neglected tropical diseases (NTDs). The fund efficiently puts private capital to work, advocating for NTD programs that are innovative, integrated, and cost-effective. It facilitates strong partnerships with the private sector, government partners, and local implementing partners to collaboratively support national disease programs. This is done through a proven implementation model that is tailored to meet the needs of individual countries, with the view to fostering healthier communities, protected from the risks of NTDs. Since its founding in 2012, along with partners, the END Fund has distributed over one billion treatments across thirty one countries, performed over 43,000 blindness and disability-preventing surgeries, and trained nearly 3.5 million health workers to preempt and treat NTDs. Learn more at www.endfund.org .
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com .
For more information please contact:
Kabir Dave, Senior Associate, BB Partners
